Table 1. Patient characteristics.
| N | Percentage (%) | |
|---|---|---|
|
Clinical stage at dx of muscle invasive disease | ||
| T1 | 1 | 1 |
| T2–T3a | 9 | 11 |
| T3b | 3 | 4 |
| T4 | 5 | 6 |
| Any T, N+ | 8 | 10 |
| Any T, any M, M+ | 27 | 33 |
| Unknown | 30 | 36 |
|
Regimen | ||
| GC | 32 | 39 |
| MVAC | 45 | 54 |
| Unknown | 6 | 7 |
|
ECOG-PS | ||
| 0 | 46 | 55 |
| 1 | 32 | 39 |
| Unknown | 5 | 6 |
|
Visceral disease | ||
| No | 44 | 53 |
| Yes | 33 | 40 |
| Unknown | 6 | 7 |
|
Response | ||
| CR | 8 | 10 |
| PR | 37 | 45 |
| SD | 11 | 13 |
| PD | 8 | 10 |
| Unknown | 19 | 23 |
|
PFS | ||
| <4 months | 8 | 10 |
| >9–12 months | 29 | 36 |
Abbreviations: CR=complete response; dx=diagnosis; ECOG-PS=Eastern Cooperative Oncology Group-performance status; GC=gemcitabine and cisplatin; MVAC=methotrexate, vinblastine, doxorubicin and cisplatin; PFS=progression free survival; PR=partial response; SD=stable disease.